Trial Profile

A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Jun 2024 According to an IGC Pharma media release, data from this study published in the European Society of Medicine Journal.
20 Jul 2023 Results of preliminary data on the application of The Columbia-Suicide Severity Scale (C-SSRS) dementia due to Alzheimers disease patients , presented at the Alzheimer's Association International Conference 2023
20 Jul 2023 Preliminary data assessing improvement in NPI-agitation (NPI-ag) scores and associated caregiver distress (NPI caregiver distress, NPI-D) scores, presented at the Alzheimer's Association International Conference 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com